Inhibitor Therapeutics (Inhibitor Therapeutics) Return-on-Tangible-Equity : -55.23% (As of Mar. 2024)

Inhibitor Therapeutics Return-on-Tangible-Equity Chart

Inhibitor Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Return-on-Tangible-Equity		Get a 7-Day Free Trial					-	-	-	517.90	-44.57

Inhibitor Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Return-on-Tangible-Equity	Get a 7-Day Free Trial															-26.91	-35.24	-39.22	-79.56	-55.23

Competitive Comparison of Inhibitor Therapeutics's Return-on-Tangible-Equity

For the Biotechnology subindustry, Inhibitor Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibitor Therapeutics's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Inhibitor Therapeutics's Return-on-Tangible-Equity falls into.

Inhibitor Therapeutics Return-on-Tangible-Equity Calculation

Inhibitor Therapeutics's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Inhibitor Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

Inhibitor Therapeutics  (OTCPK:INTI) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

Inhibitor Therapeutics Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Inhibitor Therapeutics's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibitor Therapeutics (Inhibitor Therapeutics) Business Description